ClinicalTrials.gg
Active, not recruitingNCT07000266Updated Jun 2, 2025

The RECOVERY Study: Using Supersaturated Oxygen Therapy To Treat Small Vessel Blockages After a Heart Attack

An interventional study of Percutaneous Coronary Intervention (PCI) and Diagnostic Imaging in Anterior STEMI, sponsored by Fundacio Privada Mon Clinic Barcelona. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-02.

Sponsored by Fundacio Privada Mon Clinic Barcelona · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in ST Elevation Myocardial Infarction with a site in Spain — 4 open to participants now, 10 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Spain.

Planned enrollment
26th of 27
20 · median 450
Started
2025
with 3 others
No phase
16 of 41
1 open now
Registered
37th of 41
by date

Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, this one is the 26th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 with no phase, and was the 37th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 41 studies in ST Elevation Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in ST Elevation Myocardial Infarction with a site in Spain, or all of them as a file.
02

Study summary

The study tests whether adding supersaturated oxygen (SSO₂) therapy to standard stent treatment can improve heart recovery after a major heart attack (anterior STEMI). Adults treated within 6 hours of symptoms will be randomly assigned to receive either standard care or standard care plus SSO₂. The goal is to see if SSO₂ reduces damage to small heart vessels. Heart function will be checked immediately, after one hour, and again at six months. Follow-up visits will track recovery for up to a year.

Read the detailed description

This is an investigator-initiated, post-market clinical investigation, interventional, prospective, randomized, controlled, open-label, monocenter study, in subjects with anterior STEMI with two parallel arms comparing the efficacy of SSO2 with standard PCI and standard PCI alone on reduction of microvascular resistances (Rµ)

Patients will be ≥ 18 years old and diagnosed with a first anterior STEMI requiring stent placement, symptoms duration of ≤ 6 hours and culprit lesion in the left anterior descending (LAD) artery with a TIMI (Thrombolysis In Myocardial Infarction) flow 0 or 1 without collateral circulation.

Patients who provide informed consent will be treated with primary PCI with stenting. Once the coronary blood flow is re-established, and after general and angiographic inclusion and exclusion criteria are confirmed, patients will be randomized and enrolled in the study.

A total number of 20 patients will be randomized (1:1) to SSO2 plus PCI arm or standard PCI control arm. Once randomized, SSO2 arm patients will receive SSO2 therapy inside the catheterization laboratory, meanwhile patients randomized in the standard arm will not receive further treatment beyond standard of care.

For both arms, coronary invasive measurements will be performed immediately and 60 minutes after coronary blood flow restoration and then at 6 months timepoint. Baseline clinical and procedural variables will be collected. There will be a clinical follow-up at 30 days ± 7 days, 6 months ± 1 month and 1 year ± 1 month after index event.

03

Conditions studied

  • Anterior STEMI

Keywords

  • TherOx DownStream System
  • Microvascular obstruction
  • Supersaturated oxygen therapy
  • SSO2
  • Percutaneous Coronary Intervention (PCI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must be ≥ 18 years of age
  2. Anterior STEMI ( with persistent elevation ≥ 2 mm (0.2 mV) in 2 or more contiguous anterior precordial leads (V2, V3, V4) in men or ≥ 1.5 mm (0.15 mV) in women.
  3. Symptoms consistent with myocardial ischemia (persistent chest pain, dyspnea, nauseas/vomiting, fatigue, palpitations or syncope) present for ≤ 6 hours.
  4. Provision of by patient
  5. Culprit lesion in proximal or mid LAD.
  6. Pre-PCI TIMI flow 0-1.
  7. The patient is eligible for primary PCI.
  8. Successful PCI of a proximal or mid LAD lesion with commercially available coronary stents and achievement of TIMI 2 or 3 flow
  9. Expected ability to place the catheter in the left main coronary ostium to deliver SSO2 therapy with stable and coaxial alignment.

Exclusion criteria

Exclusion Criteria:

  1. Previous MI, PCI or CABG occurred before index procedure.
  2. Previous history of stroke, (TIA) or reversible ischemic neurological deficit within last 6 months.
  3. Known severe kidney disease ( \<=30 mL/min/1.73) and/or hemodialysis.
  4. Known coagulopathy.
  5. Known ongoing anticoagulant treatment.
  6. Known large pericardial effusion or cardiac tamponade.
  7. Known allergies to polyurethanes, PET or stainless steel.
  8. Unconscious at presentation.
  9. Need for circulatory support.
  10. Need for invasive mechanical ventilation.
  11. Need for temporal intravenous pacemaker.
  12. Cardiopulmonary resuscitation (CPR) cardiac arrest ≥ 5 minutes whom baseline neurologic status is not present.
  13. Patients confirmed as pregnant.
  14. Active participation in another drug or device trial.
  15. Known for adenosine administration (severe asthma, complicated AV block, critical aortic stenosis, severe cardiac arrhythmias, severe valve diseases).
  16. Patient not suitable for femoral access.
  17. Patients with mechanical complications of STEMI.
  18. Known epicardial stenosis on LAD lesion after stent placement that restricts flow with the SSO2 delivery catheter in place.
  19. Ipsilateral insertion of a second sheath in a single femoral artery for SuperSaturated Oxygen Therapy is strictly contraindicated
  20. Presence of an intra-aortic balloon pump.
  21. Presence of a post-intervention non-stented coronary dissection or perforation.
  22. Cardiac valvular stenosis or insufficiency, pericardial disease or non-ischemic cardiomyopathy.
  23. Cardiogenic shock.
  24. Subjects with ventricular pseudoaneurysm, VSD, or severe mitral valve regurgitation (with or without papillary muscle rupture).
  25. \< 10 g/dL.
  26. Gastrointestinal or genitourinary bleeding within the last two months, or any major surgery (including CABG) within six weeks of procedure.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Standard Percutaneous Coronary Intervention (PCI) plus supersaturated oxygen (SSO2) therapy

    Treatment group

    Procedure: Percutaneous Coronary Intervention (PCI) · Diagnostic Test: Diagnostic Imaging · Device: Device Treatment · Procedure: Follow-up at 30 days · Procedure: Follow-up at 60 days · Procedure: Follow-up at 12 months

  • Experimental
    Standard Percutaneous Coronary Intervention (PCI)

    Control group

    Procedure: Percutaneous Coronary Intervention (PCI) · Diagnostic Test: Diagnostic Imaging · Procedure: Follow-up at 30 days · Procedure: Follow-up at 60 days · Procedure: Follow-up at 12 months

Interventions

  • ProcedurePercutaneous Coronary Intervention (PCI)

    Standard PCI intervention

  • Diagnostic testDiagnostic Imaging

    Cardiac Magnetic Ressonance (CMR) and hospital discharge

  • DeviceDevice Treatment

    SSO2 therapy

  • ProcedureFollow-up at 30 days

    Remote (phone) follow-up at 30 days

  • ProcedureFollow-up at 60 days

    In person follow-up at 60 days

  • ProcedureFollow-up at 12 months

    Remote (phone) follow-up at 12 months

06

What researchers measure

Primary outcomes

  1. Effect of SSO2 on microvascular resistances (Rµ)

    Superiority in % of patients without microvascular dysfunction (defined as microvascular resistance \>500 WU) of SSO2 arm versus standard of care (90% of patients with microvascular dysfunction in the control arm vs. 30% in the SSO2 arm)

    Time frame: 60 minutes after primary PCI

Secondary outcomes

  1. Effect of SSO2 on absolute coronary flow (Q)

    Absolute coronary flow (Q): difference in Q, between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.

    Time frame: At 60 minutes and at 6 months after primary PCI

  2. Effect of SSO2 on the index of microvascular resistance (IMR)

    Microvascular resistances (Rµ): difference in (Rµ) between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.

    Time frame: Within 5 minutes after primary PCI, at 60 minutes after primary PCI and at 6 months after primary PCI

  3. Effect of SSO2 on the index of microvascular resistance (IMR)

    Index of microvascular resistance (IMR): difference in IMR between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.

    Time frame: Within 5 minutes after primary PCI, at 60 minutes after primary PCI and at 6 months after primary PCI

  4. Effect of SSO2 on the coronary flow reserve (CFR)

    Coronary flow reserve (CFR): difference in CFR between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.

    Time frame: Within 5 minutes after primary PCI, at 60 minutes after PCI and at 6 months after primary PCI

  5. Effect of SSO2 on the microvascular resistance reserve (MRR)

    Microvascular resistance reserve (MRR): difference in MRR between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.

    Time frame: Within 5 minutes after primary PCI, at 60 minutes after primary PCI and at 6 months after primary PCI

  6. Effect of SSO2 on infarct size and microvascular obstruction at CMR

    Quantification of infarct size as a percentage of left ventricular mass using late gadolinium enhancement (LGE) and assessment of microvascular obstruction (MVO) presence and extent.

    Time frame: At CMR 3-5 days after primary PCI

  7. Risk of predefined major cardiovascular adverse events (MACE) during treatment and follow-up

    Time from randomization to the first occurrence of any event in the predefined MACE composite per patient.

    Time frame: During treatment, during follow-up at 30 days, 60 days and 12 months follow-ups

  8. Risk of predefined major cardiovascular adverse events (MACE) during treatment and follow-up

    Per-patient rate of composite MACE events (first and subsequent)

    Time frame: At at 30 days, 6 months and 1 year follow-ups after index PCI

Other outcomes

  1. Effect of SSO2 on ventricular remodeling

    Proportion of patients with adverse ventricular remodeling, defined as a Δ ≥20% in end-diastolic volume (EDV) or a Δ ≥15% in end-systolic volume (ESV), with additional assessment of myocardial tissue characteristics using T2-weighted imaging and LGE.

    Time frame: From baseline to follow-up CMR

  2. Effect of SSO2 on left ventricular hypertrophy

    Proportion of patients with left ventricular hypertrophy in the SSO2 therapy arm compared to the standard PCI control arm, as assessed by CMR. Left ventricular hypertrophy is considered for masses above 106.2 g/m2 for men and 84.6 g/m2 in women

    Time frame: At CMR 3-5 days after primary PCI

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 23 months is below that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
Jun 2, 2025
StartActual
May 23, 2025
Primary completionEst.
May 16, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07000266
Lead sponsor
Fundacio Privada Mon Clinic Barcelona
Responsible party
Sponsor
First posted
Jun 2, 2025
Start date
May 23, 2025
Primary completion
May 16, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion